Latest News

MEDICAL NEWS
POSTED BY CARA SCHILLINGER ON 7/5/2012

STOCKHOLM, June 28, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Esbriet® (pirfenidone) on Sweden's list of reimbursed drugs, making Esbriet the first medicine for the treatment of idiopathic pulmonary fibrosis (IPF) to be reimbursed in Sweden.

MEDICAL NEWS
POSTED BY CARA SCHILLINGER ON 4/7/2012

France's Transparency Commission (CT) Issues Favorable Opinion for Reimbursement of Esbriet® (pirfenidone)

-- InterMune expresses confidence in ASCEND Phase 3 study outcome; updates timeline --
-- Company to conduct conference call and webcast at 4:30 p.m. EDT today --

MEDICAL NEWS
POSTED BY CARA SCHILLINGER ON 3/15/2012

Decision applies to all adult patients with mild-to-moderate IPF - InterMune to conduct conference call and webcast at 4:00 PM EDT on 3/15/2012

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 10/27/2011

Results of a study performed at the University of Pittsburgh Medical Center (UPMC) reports that high concentrations of specific proteins in the blood of patients with idiopathic pulmonary fibrosis (IPF) that also met specific clinical parameters predicted poor overall survival.

MEDICAL NEWS
POSTED BY CARA SCHILLINGER ON 10/21/2011

NIH stops one treatment arm of trial; other two treatments to continue

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 10/7/2011

Study points to a phosphorylation pathway that may contribute to the development of lung injury and fibrosis

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 10/6/2011

By Dr. Daniel Dilling, FCCP

Lung transplantation, at one time, seemed like science fiction, but innovations in surgical technique and immunosuppression made it clinical reality. Limited supply of donor lungs and the vagaries of immunosuppression still limit its success.

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 10/4/2011

Oyster Bay, N.Y. – Dr. Yang Zhou, associate research scientist working in Dr. Jack Elias’s lab at the Yale University School of Medicine, has been awarded a grant to investigate potential biomarkers and therapeutic targets of pulmonary fibrosis.

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 9/23/2011

By Charles Bankhead, Staff Writer, MedPage Today
Published: September 22, 2011
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner

MEDICAL NEWS
POSTED BY PULMONARY FIBROSIS FOUNDATION ON 9/12/2011

Launches in other European countries to follow in 2012

Conference call and webcast scheduled today at 8:30 a.m. EDT